Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.

Hiển thị phiên bản (1) khác

Vascular endothelial growth factor A (VEGF-A) and vascular endothelial growth factor receptor 2 (VEGFR2) are the key factors mediating neo-vascularization. They are often coexpressed in breast cancer. Sex steroids may stimulate angiogenesis via the estrogen receptor (ER) pathway. We investigated to...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính:	Mele, T, Generali, D, Fox, S, Brizzi, M, Bersiga, A, Milani, M, Allevi, G, Bonardi, S, Aguggini, S, Volante, M, Dogliotti, L, Bottini, A, Harris, A, Berruti, A
Định dạng:	Journal article
Ngôn ngữ:	English
Được phát hành:	2010

Những quyển sách tương tự

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
Bằng: Mele, T, et al.
Được phát hành: (2010)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
Bằng: Fox, S, et al.
Được phát hành: (2011)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
Bằng: Fox, S, et al.
Được phát hành: (2011)

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
Bằng: Generali, D, et al.
Được phát hành: (2009)

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
Bằng: Generali, D, et al.
Được phát hành: (2009)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer
Bằng: Generali, D, et al.
Được phát hành: (2007)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer.
Bằng: Generali, D, et al.
Được phát hành: (2007)

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Bằng: Generali, D, et al.
Được phát hành: (2008)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
Bằng: Generali, D, et al.
Được phát hành: (2006)

Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients.
Bằng: Generali, D, et al.
Được phát hành: (2006)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
Bằng: Generali, D, et al.
Được phát hành: (2006)

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
Bằng: Generali, D, et al.
Được phát hành: (2008)

Effect of primary letrozole (LET) vs letrozole plus metronomic cyclophosphamide (LET-CYC) on Treg infiltration in ER plus ve breast cancer.
Bằng: Fox, S, et al.
Được phát hành: (2006)

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
Bằng: Generali, D, et al.
Được phát hành: (2011)

DOWN-REGULATION OF HYPOXIA INDUCIBILE FACTOR-1 alpha (HIF-1 alpha) EXPRESSION, THROUGH mTOR PATHWAY, BY LETROZOLE (FEMARA (R)) IN ER plus ve BREAST CANCER PATIENTS: CLINICAL IMPLICATIONS
Bằng: Foroni, C, et al.
Được phát hành: (2009)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
Bằng: Allevi, G, et al.
Được phát hành: (2013)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
Bằng: Allevi, G, et al.
Được phát hành: (2013)

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer
Bằng: Andreis, D, et al.
Được phát hành: (2016)

The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
Bằng: Milani, M, et al.
Được phát hành: (2009)

ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment
Bằng: A Ianza, et al.
Được phát hành: (2020-06-01)

Tamoxifen for Breast Cancer
Bằng: A Karn, et al.
Được phát hành: (2010-03-01)

Nanoparticle Effect on Interaction of Epirubicin with DNA
Bằng: Leyla Karadurmus, et al.
Được phát hành: (2017-11-01)

WITHDRAWN: Tamoxifen for early breast cancer.
Bằng: Clarke, M
Được phát hành: (2008)

Vitamin C-driven epirubicin loading into liposomes
Bằng: Lipka D, et al.
Được phát hành: (2013-09-01)

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
Bằng: Kerstin Wimmer, et al.
Được phát hành: (2023-11-01)

Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
Bằng: Andreas Venizelos, et al.
Được phát hành: (2022-08-01)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
Bằng: Yuntao Wang MS, et al.
Được phát hành: (2021-03-01)

Screening of oral tamoxifen ocular toxicity in patients with breast cancer
Bằng: Ahmed Tharwat, et al.
Được phát hành: (2022-01-01)

Modern breast cancer therapy: from tamoxifen to T-cell engineering
Bằng: Yu. A. Shevchenko, et al.
Được phát hành: (2022-11-01)

Tamoxifen in breast conservation therapy.
Bằng: Lee, K, et al.
Được phát hành: (1995)

Efficacy and safety of pegylated liposomal doxorubicin and epirubicin as neoadjuvant chemotherapy for breast cancer
Bằng: Yuanyuan Shen, et al.
Được phát hành: (2024-12-01)

Effect of Two Administration Methods of Endostar Combined with Epirubicin on Breast Cancer in Mice
Bằng: WU Jiao, et al.
Được phát hành: (2018-07-01)

The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer
Bằng: Liu L, et al.
Được phát hành: (2017-06-01)

Cardiac troponin T for early detection of cardiotoxicity in breast cancer patients treated with epirubicin
Bằng: Erdim Refik, et al.
Được phát hành: (2009-09-01)

Differential assessment of angiogenic activity and of vascular survival ability (VSA) in breast cancer.
Bằng: Giatromanolaki, A, et al.
Được phát hành: (2002)

Early and late tamoxifen resistance in breast cancer
Bằng: Abu Rabi Z., et al.
Được phát hành: (2010-01-01)

Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
Bằng: Seo Yun Moon, et al.
Được phát hành: (2021-08-01)

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
Bằng: Lundgren Steinar, et al.
Được phát hành: (2010-06-01)

Sox2 promotes tamoxifen resistance in breast cancer cells
Bằng: Marco Piva, et al.
Được phát hành: (2013-10-01)

Metabolic/hypoxial axis predicts tamoxifen resistance in breast cancer
Bằng: Hany N. Azzam, et al.
Được phát hành: (2022-09-01)